Skip to main content
TipRanks
Go Ultimate75% OFF

Skye Bioscience (SKYE) AI Stock Analysis

1,005 Followers
SKYE

Skye Bioscience

(NASDAQ:SKYE)

Select Model
Rating:40Underperform
Price Target:$0.75â–¼(-4.96% Downside)
Action:downgraded
Date:11/14/26

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and sustained cash burn alongside a shrinking equity cushion). Technicals also point to a bearish trend with the price below key moving averages and negative MACD. Corporate events provide some offset via merger/financing developments, but Nasdaq compliance and delisting risk temper that benefit; valuation signals are limited due to negative earnings and no dividend yield data.

Positive Factors
Low Reported DebtVery low reported debt limits near-term interest and repayment obligations, giving the company some balance-sheet capacity while it advances its pipeline. This reduces leverage-related pressure, although the benefit is moderated by the company’s severely diminished equity base and ongoing cash needs.
Negative Factors
Pre-Revenue Operating ModelWith no reported revenue base, Skye lacks commercial cash inflows to support research and development internally. Continued operating losses leave results dependent on clinical progress and future financing, making the path to sustainable profitability uncertain over the next several quarters.

Skye Bioscience (SKYE) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%SKYE-92.44%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.48M
Dividend Yield
―
Average Volume (3M)
85.95K
Price to Earnings (P/E)
-0.1
Beta (1Y)
3.75
Revenue Growth
―
EPS Growth
26.40%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Skye Bioscience Business Overview & Revenue Model

Company Description

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripher...

Skye Bioscience Earnings Call Summary

Earnings Call Date:Nov 10, 2025(Q3-2025)|% Change Since:-93.08%|Next Earnings Date:Mar 25, 2027
Earnings Call SentimentNeutral

The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.

Positive Updates

Strong Financial Position
Skye Bioscience ended the third quarter with cash and cash equivalents totaling $35.3 million, which is expected to fund operations and key clinical milestones into 2027.

Negative Updates

Increased R&D Expenses
R&D expenses for Q3 2025 increased to $9.4 million from $4.9 million in Q3 2024, primarily due to contract manufacturing and clinical trial costs.

Company Guidance

In the Skye Bioscience, Inc. third-quarter 2025 earnings call, the company provided detailed guidance on its financial and clinical development milestones. Key financial highlights included ending the quarter with $35.3 million in cash and equivalents, with expectations to fund operations into 2027. R&D expenses increased to $9.4 million from $4.9 million in the previous year due to ongoing clinical trials, including those for Nolasimab and Nimazumab. Notably, the company reported a net loss of $12.8 million, attributed partly to non-cash share-based compensation expenses. Clinical updates focused on the promising results from the Phase 2a CBEYOND study, showing a 3% additional weight loss with Nimazumab plus semaglutide compared to semaglutide alone, with a significant p-value of 0.0372. The study also demonstrated improvements in lean to fat mass ratio and reduced waist circumference, with retention strong in the extension study. The company is advancing Nimazumab's dose concentration strategy and plans to evaluate higher doses in future studies, keeping scalability and patient convenience in focus.

Skye Bioscience Financial Statement Overview

Summary

Financials reflect a pre-revenue biotech with $0 revenue, persistent and sizable net losses, and continued negative operating/free cash flow (TTM operating cash flow about -$30.6M). While reported debt is minimal, the equity base has sharply deteriorated over time, reducing financial flexibility and increasing financing risk.

Income Statement

12Very Negative

Balance Sheet

42Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-204.21K-723.35K0000
EBITDA-42.16M-55.20M-25.29M-36.62M-18.70M-7.72M
Net Income-37.67M-55.92M-26.57M-37.64M-19.48M-8.52M
Balance Sheet
Total Assets5.07M28.31M72.76M11.94M9.11M9.86M
Cash, Cash Equivalents and Short-Term Investments4.82M25.74M68.42M1.26M1.24M8.98M
Total Debt9,452273.65K455.59K4.62M1.98M2.14M
Total Liabilities3.71M8.29M4.61M14.07M12.12M3.99M
Stockholders Equity1.36M20.02M68.15M-2.13M-3.01M5.86M
Cash Flow
Free Cash Flow-30.58M-43.07M-26.84M-13.96M-12.77M-6.57M
Operating Cash Flow-30.58M-43.06M-25.24M-13.95M-12.74M-6.47M
Investing Cash Flow17.23M-19.50M-245.62K6.60M5.21M-90.87K
Financing Cash Flow-277.84K29.57K83.56M16.44M-208.79K13.08M

Skye Bioscience Technical Analysis

Technical Analysis SentimentNegative
Last Price0.79

Price Trends

50DMA1.47Negative
100DMA2.69Negative
200DMA4.38Negative

Market Momentum

MACD-0.18Negative
RSI31.95Neutral
STOCH56.41Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKYE, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.47, and below the 200-day MA of 4.38, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 31.95 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKYE.

Skye Bioscience Risk Analysis

Skye Bioscience disclosed 82 risk factors in its most recent earnings report. Skye Bioscience reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Some of our executive officers and directors have interests in the Transaction that are different from our stockholders and that may influence them to support or approve the Transaction without regard to the interests of our stockholders.Q2, 2026
2.Our stockholders may not realize a benefit from the Transaction commensurate with the ownership dilution they will experience in connection with the Transaction.Q2, 2026
3.Our equityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Transaction as compared to their current ownership and voting interests in the respective companies.Q2, 2026

Skye Bioscience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SKYE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ATNMATNM54Neutral$33.64M3.2465.18%―38788.89%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
INMBINMB49Neutral$27.68M-1.44-81.71%―-100.00%71.08%
OTLKOTLK46Neutral$97.62M-0.36222.01%―――
SKYESKYE40Underperform$3.48M-0.10-503.95%――26.40%
LTRNLTRN40Underperform$4.51M-0.24-674.37%――32.93%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SKYEATNMOTLKINMBLTRNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SKYE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SKYESkye Bioscience, Inc.0.79-8.53-91.57%
ATNMActinium Pharmaceuticals1.07-0.26-19.55%
OTLKOutlook Therapeutics0.40-1.48-78.67%
INMBInmune Bio0.89-0.62-40.79%
LTRNLantern Pharma, Inc.0.28-2.74-90.63%

Skye Bioscience Corporate Events

Legal Proceedings

Skye Bioscience Wins Jury Verdict in Employee Retaliation Lawsuit

Positive
Nov 12, 2026

A former Skye Bioscience employee filed a lawsuit alleging violations of Sarbanes-Oxley whistleblower protections and retaliation under California law over actions and events involving the company’s former management during employment from March 2018...

Business Operations and StrategyExecutive/Board Changes

Skye Bioscience CFO Resigns, CEO Assumes Financial Role

Neutral
Sep 11, 2026

On September 8, 2026, Skye Bioscience terminated its Master Services Agreement with Lohman & Associates, coinciding with the resignation of Chief Financial Officer and principal financial and accounting officer John P. Sharp. The company stated that...

Business Operations and StrategyPrivate Placements and Financing

Skye Bioscience Establishes New Equity Financing Arrangements

Positive
Aug 24, 2026

On August 21, 2026, Skye Bioscience entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P., establishing an equity line of credit of up to $22 million in common and non-voting common shares, with the final amount co...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026